Patient P-01406

Synthetic patientNBL-101 · Day 115 · 65–74 · F · baseline S18Open companion preview

Therapy response

Declining

Tolerance

Improving

GI state

Deteriorating

Inflammatory state

Deteriorating

Nutritional resilience

Unstable

Discontinuation risk

58%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S18
Day 48 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 51 GI-04 recommended — GI Support Protocol GI-04
Day 52 Patient accepted — Started GI-04 in the companion
Day 60 GI symptom burden −35% vs expected — GI Support Protocol GI-04
Day 66 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 48.

Primary contributors, last 14 days

Inflammatory activity+7
Toxicity-7
GI instability+4
Nutritional resilience-3
Treatment adherence+2

What helped?

GI Support Protocol GI-04Day 51
Result: symptom burden −35%

LIFE OS recommendation

Dietary Support Protocol NP-02

56%

probability of meaningful tolerance improvement

284 similar trajectories
66% showed improvement
median effect visible after 10 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Mucosal barrier integrity ↓80
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 49 and rising
Inflammatory signalling ↑65
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 52
- WearableHRV 26 ms, trending down
Butyrate / short-chain fatty acid production ↓55
- MicrobiomeButyrate capacity 42/100
- Daily logFibre intake low in recent food logs
Autonomic recovery ↑25
- WearableResting HR 74 bpm
Drug metabolism and exposure ↑20
- BloodToxicity index 41

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Normal metabolizer
Expected exposure
MTHFR C677T
Reduced folate turnover

Microbiome

Shannon diversity 2.6 · butyrate capacity 42/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiNormal
Bacteroides fragilisNormal
Bifidobacterium longumLow
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 28 ms
Sleep: 6.7 h
Steps: 4,197
Resting HR: 77 bpm

Daily log: GI score 49, nutritional resilience 40, adherence 50.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Keep the sleep window steady
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01661	53%	S03	GI-04	improved	52
P-01692	53%	S14	NP-02	improved	49
P-01496	52%	S14	SC-12	improved	46
P-01327	51%	S01	GI-04	improved	56
P-01462	51%	S14	NP-02	improved	47
P-01482	51%	S14	GI-04	improved	47
P-01330	50%	S14	GI-04	improved	47
P-01709	50%	S14	GI-04	improved	43
P-01433	49%	S14	GI-04	improved	48
P-01573	49%	S14	GI-04	improved	49
P-01624	49%	S14	GI-04	improved	52
P-01879	49%	S14	SC-12	improved	51